BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

BioMarin Pharmaceutical BMRN reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin is a biotechnology company “dedicated to transforming lives through genetic discovery.” The company develops and commercializes targeted therapies that address the root cause of ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target dropped by equities research analysts at Citigroup from $93.00 to $81.00 in a research report issued on Wednesday, Benzinga ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a research ...